H.C. Wainwright raised the firm’s price target on Acelyrin to $18 from $16 and keeps a Buy rating on the shares. The firm updated estimates to adjust for a previous error.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRN:
Questions or Comments about the article? Write to editor@tipranks.com